Blog

The Attorney General’s Final Order Rescheduling Medical Marijuana to Schedule III: What It Does, and What It Means for Medical Marijuana Licensees

Summary: Acting Attorney General Todd Blanche’s Final Order, effective April 22, 2026, moves two categories of marijuana products to Schedule III: FDA-approved drug products containing marijuana, and medical marijuana products manufactured, distributed, or dispensed under a state license. Everything else stays on Schedule I. To claim Schedule III status, state-licensed medical marijuana operators must register with the DEA. A 60-day early-bird window triggers a six-month expedited review and interim Schedule III treatment. The tradeoff is real federal oversight, a new inventory sale-and-buyback regime for cultivators, and tight tethering to the state license. Tax, banking, and intellectual property consequences are potentially significant but not automatic.

A Practical Guide for State-Licensed Operators

What the Order Does

The Final Order amends 21 C.F.R. Parts 1300, 1301, 1308, and 1312 and moves two categories of marijuana products to Schedule III under the Controlled Substances Act:

FDA-approved drug products containing marijuana, and
Medical marijuana products that “are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana products containing marijuana for medical purposes.”

The Final Order applies to only marijuana, its extracts, and naturally occurring Delta-9-THC derived from the cannabis plant, other than the mature stalks and seeds.

Everything else previously on Schedule I remains on Schedule I. Adult-use cannabis licensees are not covered. Neither are THC-containing hemp products above the federal limit, nor synthetic cannabinoids. If a product is not tied to a state medical marijuana license or an FDA approval, this order does not move it.

The Department of Justice simultaneously announced an “expedited” rescheduling hearing for the remaining Schedule I cannabis substances. That hearing is set for June 29, 2026.

DEA Registration for Medical Marijuana Licensees

The Final Order’s does not require state-licensed medical marijuana operators to follow the usual FDA and DEA pharmacy and controlled substances rules for prescribing and dispensing controlled substances. Instead, the DEA will piggyback on existing state medical marijuana licensing systems

State-licensed medical marijuana operators must register with the DEA to obtain Schedule III status. The new 21 C.F.R. § 1301.13(k) creates an expedited review process for early applicants. Operators who file within the first 60 days after the rule’s publication in the Federal Register are entitled to a six-month review period, and their registrations carry interim Schedule III status while the application is pending. Registration is not guaranteed, but it is highly likely assuming an applicant demonstrates they are a state-licensed medical marijuana operator eligible under the Final Order.

There are three registration types, and an state-licensed medical marijuana operator can register for more than one type, depending on their scope of activities:

Manufacturers: This type applies cultivation, production, processing, packaging, labeling, and transfer of marijuana and marijuana products to registered distributors or other registered manufacturers.
Distributors: This type applies to those who receive marijuana and marijuana products from registered manufacturers and transfer them to registered dispensers or other registered distributors.
Dispensers: This type applies to those who dispense marijuana and marijuana products to individuals authorized under state law to possess them for medical purposes.

A vertically integrated operator must register for each activity it conducts. A non-vertical operator must confirm that its DEA registration matches the scope of its state authority. Schedule III status attaches only to activities the state agency has actually authorized. If the state license is suspended, revoked, or allowed to expire, the DEA registration is automatically suspended along with it.

New DEA Requirements: Fees, Inspections, and Labels

The DEA retains authority to impose whatever additional requirements it considers necessary to honor the Single Convention on Narcotic Drugs.

The most newsworthy of these to date is the new inventory handling requirement for cultivators. A cultivator with a DEA manufacturer license must sell its harvested crop to the DEA for a fee, and the DEA will then sell the crop back to the manufacturer with an administrative fee layered on top. Until the sale-and-buyback cycle is complete, the marijuana must be stored in a facility to which the DEA “maintains access.” The cultivation application must specify where cultivation is permitted under the state license, and the DEA may inspect post-harvest storage areas on demand.

A less onerous requirement is that all medical marijuana labels must include the warning required by 21 U.S.C. § 825(c) stating that it is a crime to transfer the drug to any person other than the patient for whom it was prescribed. Packaging, labeling, disposal, and security rules are otherwise left to state medical marijuana programs.

Implications of Treating Medical Marijuana as a Pharmaceutical Drug

While state-licensed operators do not currently offer FDA-approved marijuana products, they should monitor developments in this area following the Final Order. FDA approval can be a time-consuming and lengthy process, but with it comes greater eligibility for medical insurance coverage for medical marijuana patients.

As with DEA regulation and enforcement, FDA regulation carries potential risks and rewards, and it is unclear how the medical marijuana industry will be affected by the Final Order and subsequent changes flowing from it as it relates to the treatment of medical marijuana products as federally recognized pharmaceutical drugs.

Tax, Banking, and Intellectual Property Implications

For most state-licensed medical marijuana operators, Section 280E of the Internal Revenue Code has been the most painful federal cost of doing business. As of March 23, 2026, the IRS has indicated that it will not assess 280E penalties on DEA-licensed medical marijuana operators as of the Final Order’s effective date. While the DEA Administrator “encouraged” retroactive 280E tax relief, the IRS does not yet appear willing to provide that.

Banking is a harder problem. 18 U.S.C. § 1956 prohibits financial transactions involving proceeds of criminal activity, which has long included marijuana sales that violate the CSA. The Bank Secrecy Act and FinCEN guidance layer additional hurdles onto cannabis banking, and rescheduling by itself does not clear them. Additional federal statutes and regulations will have to move before mainstream banking becomes routine. Card networks and other digital payment rails may loosen sooner, which would begin to erode the cash-centric posture of dispensary operations.

Trademark protection should come faster. Cannabis companies have historically been shut out of federal trademark registration because their underlying commerce violated federal law. The U.S. Patent and Trademark Office has already issued registrations to hemp companies for federally legal activities. The same reasoning should extend to DEA-registered medical marijuana licensees for their now-Schedule III operations.

What to Do Next

State-licensed medical marijuana operators should sit down with their legal and tax teams and evaluate the DEA registration process. For most, the math will favor registration. Avoiding 280E treatment, even prospectively, will generally outweigh the incremental compliance burden of direct DEA oversight. The 60-day early-bird window for expedited review and interim Schedule III status compresses that decision.

While the language of the Final Order does not appear to make registration mandatory, there is a risk that medical marijuana licensees who do not register may be subject to future DEA enforcement for conducting unlicensed activities with Schedule III drugs in violation of 21 CFR. This should be another consideration in the decision of whether or not to apply.

Before filing:

Audit security and inventory tracking procedures against every applicable state medical marijuana rule. Pay particular attention to inventory management and diversion controls.
Confirm that packaging and labeling meet both state requirements and add the required Section 825(c) warning. Note: Florida MMTCs likely already comply because they are required to include this warning under existing state law.
Work with your financial advisors to document your date of Schedule III treatment and ensure that you maximize your eligibility for deductions of eligible business expenses.
Retain counsel who practices in this area. Verify your state license is in good standing, because your DEA registration will rise and fall with it.

Regardless of where you sit in the cannabis industry, the June 29, 2026 hearing on the remaining Schedule I substances is the next inflection point. Plan around it.

Risks

The expedited review window is short, and being early confers interim Schedule III status that later filers will not enjoy. Operators who wait will be competing for DEA review capacity against the first wave and will carry Schedule I status during the interim.

The DEA registration is only as durable as the state license. A suspension, revocation, or lapse on the state side triggers automatic federal suspension, with all the enforcement and reputational consequences that follow.

The 280E relief is aspirational, not operative. The Final Order contains an encouragement to Treasury; it is not a Revenue Ruling, a regulation, or a statutory amendment. Tax positions should be taken on current law, not on anticipated relief.

Banking is still hard. Rescheduling does not repeal the Bank Secrecy Act or the money laundering statutes, and operators who assume otherwise will find their depository relationships fragile.

The Final Order’s scope is marijuana tethered to a state medical license. Adult-use operations, non-compliant hemp, and synthetic cannabinoids remain Schedule I. Companies with mixed lines of business should be careful about cross-contamination, both legal and operational.

A Note on Counsel

This post is orientation, not legal advice. The DEA registration process, the interplay between state licensing and federal registration, and the tax and banking implications are all fact-specific. Before you file a registration application, before you restructure operations in reliance on Schedule III status, and certainly before you take a tax position premised on 280E relief, speak with qualified counsel.

This post addresses federal rescheduling of medical marijuana under the Controlled Substances Act and its interaction with state medical marijuana licensing regimes. Requirements are subject to change as the DEA, Treasury, and state agencies implement the order. Readers should confirm current requirements with qualified legal counsel before relying on any information contained here.